A human pan-cancer system analysis of regulator of chromatin condensation 2
Siming Gong,
Hao Wu,
Changwu Wu,
Yingjuan Duan,
Bixi Zhang,
Panfeng Wu,
Juyu Tang,
Jinfei Fu
Affiliations
Siming Gong
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Institute of Anatomy, University of Leipzig, Leipzig, Germany
Hao Wu
Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, China
Changwu Wu
Institute of Anatomy, University of Leipzig, Leipzig, Germany
Yingjuan Duan
Faculty of Chemistry and Mineralogy, University of Leipzig, Leipzig, Germany
Bixi Zhang
Department of Pathology, Hunan Provincial People's Hospital, Hunan Normal University, Changsha, China
Panfeng Wu
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Juyu Tang
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Jinfei Fu
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Corresponding author. Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
Regulation of chromosome condensation 2 (RCC2) is associated with the cell cycle and is a crucial regulator of the chromatin condensation 1 (RCC1) family. The members of this family were normally regulators in the process of DNA replication and nucleocytoplasmic transport. RCC2 overexpression may lead to tumor formation and poor prognosis in some tumors including breast cancer and lung adenocarcinoma. However, the possible role of RCC2 in tumor formation and its prognostic function remains unclear. In this study, expression analysis from databases including The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) were combined to perform the first integrative and comprehensive analysis of RCC2 in human pan-cancer. RCC2 was highly expressed in most tumors which may lead to a poor prognosis. RCC2 expression was associated with immune/stromal infiltration, immune checkpoints, tumor mutational burden, and microsatellite instability. Thus, RCC2 could be a novel biomarker for prognosis and a promising cancer therapy target.
